Home Antibody All anti-IRF5 antibodies
Anti-IRF5 Antibody EPR6094
Also for IRF5 (NM_001098627)
|A synthetic peptide corresponding to residues in human IRF-5 was used as an immunogen.|
||Tissue culture supernatant
||0.5~1.0 mg/ml (Lot Dependent)
||IHC-Fr: Use at an assay dependent concentration; WB: 1:1000 - 1:10000; FC: 1:100 - 1:500
|Does not react with Mouse, Rat. Is unsuitable for ICC/IF,IHC-P or IP.|
|PBS 49%,Sodium azide 0.01%,Glycerol 50%,BSA 0.05%
|Is unsuitable for ICC/IF,IHC-P or IP.
|Homo sapiens interferon regulatory factor 5 (IRF5), transcript variant 3|
|IRF-5 is a member of the interferon regulatory factor (IRF) family, a group of transcription factors with diverse roles, including virus-mediated activation of interferon, and modulation of cell growth, differentiation, apoptosis, and immune system activity. Members of the IRF family are characterized by a conserved N-terminal DNA-binding domain containing tryptophan (W) repeats (1). |
Senescence and Autophagy
Toll-like receptor signaling pathway
* Shipping is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
Western blot - Anti-IRF5 antibody [EPR6094]; All lanes : Anti-IRF5 antibody [EPR6094] at 1/1000 dilution.Lane 1 : U937 cell lysates.Lane 2 : Ramos cell lysates.Lane 3 : THP-1 cell lysates.Lysates/proteins at 10 µg per lane.Secondary.HRP labelled goat anti-rabbit at 1/2000 dilution.Predicted band size : 56 kDa.
Flow Cytometry - Anti-IRF5 antibody [EPR6094]; Flow cytometric analysis of permeabilized U937 cells using TA310952 at 1/100 dilution (red) or a rabbit IgG (negative) (green).
Flow Cytometry - Anti-IRF5 antibody [EPR6094]; Flow cytometry analysis of Plasmacytoid dendritic cells, staining IRF5 with TA310952. .Cells were fixed in paraformaldehyde and fixed in saponin. The sample was incubated with the primary antibody (1/100 in 2% human serum + 0.5 mM EDTA) for 20 minutes at 4Â°C. An AlexaFluor?488-conjugated goat anti-rabbit polyclonal IgG (1/100) was used as the secondary antibody.Gating Strategy: FSC/SSC lymphocytes and then FSC-A/FSC-H singlets